Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Previously treated recurrent CLL~* Measurable lymphadenopathy~* Requires therapy for CLL~* Has experienced CLL progression \< 36 months since the completion of the last prior therapy~Key Exclusion Criteria:~* Recent history of a major non-CLL malignancy~* Evidence of an ongoing infection~* CLL refractory to bendamustine~* Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib+bendamustine+rituximab (Type: EXPERIMENTAL): Participants will receive idelalisib plus bendamustine and rituximab
- Placebo to match idelalisib+bendamustine+rituximab (Type: PLACEBO_COMPARATOR): Participants will receive placebo to match idelalisib plus bendamustine and rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).